Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

Published:2011-07-24 Issue:8 Volume:17 Page:941-943
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Best Timothy,Li Dalin,Skol Andrew D,Kirchhoff Tomas,Jackson Sarah A,Yasui Yutaka,Bhatia Smita,Strong Louise C,Domchek Susan M,Nathanson Katherine L,Olopade Olufunmilayo I,Huang R Stephanie,Mack Thomas M,Conti David V,Offit Kenneth,Cozen Wendy,Robison Leslie L,Onel Kenan

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2407.pdf

Reference20 articles.

1. Friedman, D.L. et al. J. Natl. Cancer Inst. 102, 1083–1095 (2010).

2. Meadows, A.T. et al. J. Clin. Oncol. 27, 2356–2362 (2009).

3. Travis, L.B. et al. J. Am. Med. Assoc. 290, 465–475 (2003).

4. Constine, L.S. et al. Int. J. Radiat. Oncol. Biol. Phys. 72, 24–33 (2008).

5. Neglia, J.P. et al. J. Natl. Cancer Inst. 93, 618–629 (2001).

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review;Cancer Epidemiology, Biomarkers & Prevention;2024-05-27

2. Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018;ESMO Open;2024-01

3. Germline genomics in radiotherapy;Machine Learning and Artificial Intelligence in Radiation Oncology;2024

4. Association between Single Nucleotide Polymorphisms of Apoptosis and Cell Cycle Control Genes and the Risk of Cancer Development in Chronically Exposed People;Biology Bulletin;2023-12

5. Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies;Cancer Immunology, Immunotherapy;2023-09-02